Holen Sie sich die Stockscreener-App
109.95
0.07%
-0.08
Handel nachbörslich:
109.90
-0.05
-0.05%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Notable analyst calls this week: Airbnb, Gilead and Snowflake stocks among top picks (MRK:NYSE) - Seeking Alpha
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise - MarketBeat
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP - Clinical Trials Arena
Some Investors May Be Willing To Look Past Gilead Sciences' (NASDAQ:GILD) Soft Earnings - Yahoo Finance
EU okays Gilead's seladelpar for primary biliary cholangitis - FirstWord Pharma
Advyzon Investment Management LLC Buys New Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Handelsbanken Fonder AB Buys 51,453 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Good Life Advisors LLC - MarketBeat
Gilead's new HIV med, a bird flu shot for chickens, and Hims does blood tests: Pharma news roundup - Quartz
Gilead Sciences: Buy Rating Backed by Strong Q4 Performance, Strategic Initiatives, and Promising Pipeline - TipRanks
Kornitzer Capital Management Inc. KS Reduces Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis - Marketscreener.com
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis - BioSpace
Kentucky Retirement Systems Insurance Trust Fund Purchases 17,439 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Valley Wealth Managers Inc. - MarketBeat
Gilead Sciences acquires $14.9 million in Arcus Biosciences stock - Investing.com
Gilead Sciences acquires $14.9 million in Arcus Biosciences stock By Investing.com - Investing.com Australia
Gilead Sciences Gets Conditional Marketing Authorization for Liver Disease Treatment in European Economic Area - Marketscreener.com
Insider Selling: Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells 2,500 Shares of Stock - MarketBeat
The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease - CSRwire.com
Gilead Sciences, Inc. (GILD): Among Stocks That Analysts Think Will Go Up - Insider Monkey
Assembly Biosciences and Gilead's genital herpes treatment gives positive results in early stage trial - Seeking Alpha
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Gilead deal staves off generic HIV drugs for another six years - Life Sciences Intellectual Property Review
Alberta Investment Management Corp Sells 151,193 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Werba Rubin Papier Wealth Management Sells 6,179 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead, Janssen Settle HIV Treatment Suits With Lupin, Apotex - Law360
CapWealth Advisors LLC Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
AustralianSuper Pty Ltd Has $105.14 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire
How Is The Market Feeling About Gilead Sciences? - Benzinga
Deutsche Bank Upgrades Gilead Sciences (BIT:1GILD) - Nasdaq
Gilead Sciences stock hits 52-week high of $106.78 - Investing.com
Gilead Passes on Option for Arcus’ Cancer Drug Despite Strong Early Data - BioSpace
Deutsche Bank Aktiengesellschaft Upgrades Gilead Sciences (NASDAQ:GILD) to "Buy" - MarketBeat
Mcdonald Partners LLC Decreases Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
FDA sets June date for Gilead's twice-yearly HIV PrEP - pharmaphorum
Gilead Sciences, Inc. (NASDAQ:GILD) Position Lifted by Convergence Investment Partners LLC - MarketBeat
Truist Financial Corp Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Callahan Advisors LLC Has $604,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
New York State Common Retirement Fund Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Blue Trust Inc. Has $326,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Principal Financial Group Inc. Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Principal Securities Inc. Purchases 4,468 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Strategic Financial Concepts LLC Makes New $6.64 Million Investment in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead new drug applications for twice-yearly Lenacapavir for HIV Prevention accepted by USFDA under... - Medical Dialogues
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use - Pharmaceutical Technology
Arcus’s Casdatifan Differentiates, But Data Overshadowed By Gilead Opting Out - News & Insights
Gilead Sciences, Inc. (NASDAQ:GILD) Short Interest Update - MarketBeat
FDA Approves NDA for Gilead's new HIV Prevention Shot - Managed Healthcare Executive
Deutsche Bank Upgrades Gilead Sciences (WBAG:GILD) - Nasdaq
Deutsche Bank Upgrades Gilead Sciences (GILD) - Nasdaq
FDA accepts Gilead’s new drug applications for lencapavir - Dallas Voice
Arcus stock falls as Gilead opts out cancer drug (RCUS:NYSE) - Seeking Alpha
Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's - Simply Wall St
Gilead stock upped, Merck stock cut at Deutsche Bank (MRK) - Seeking Alpha
Calls of the Day: Gilead Sciences and Merck - MSN
The FDA could approve a new twice-yearly HIV prevention treatment this year - Quartz
Gilead Settles Suits on Two HIV Treatments, Mooting Bench Trial - Bloomberg Law
Deutsche Bank upgrades Gilead on its HIV treatment franchise - Investing.com
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):